tert-butyl 4-(naphthalen-2-ylmethyl)piperazine-1-carboxylate | 1209468-87-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: tert-butyl 4-(naphthalen-2-ylmethyl)piperazine-1-carboxylate
• CAS: 1209468-87-0
• 化学式: C₂₀H₂₆N₂O₂
• 分子量: 326.439
• InChiKey: PNTOGCBROBMFMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  446.7±38.0 °C(Predicted)
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(naphthalen-2-ylmethyl)piperazine-1-carboxylate 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 1-(2-萘基甲基)哌嗪
  参考文献：
  名称：

  作为新型改良铁死亡抑制剂的 Ferrostatin-1 甲酰哌嗪类似物的设计、合成和评估

  摘要：

  本研究基于已知的铁死亡抑制剂铁他汀-1（Fer-1）的结构，设计并合成了一系列新型甲酰基哌嗪衍生的铁死亡抑制剂。评估了这些合成化合物在 Erastin 诱导的人脐静脉内皮细胞 (HUVEC) 中的抗铁死亡活性。研究发现，一些新化合物，特别是化合物 ，表现出有效的抗铁死亡活性，其能够恢复细胞活力、减少铁积累、清除活性氧、维持线粒体膜电位、增加 GSH 水平、降低 LPO和 MDA 含量，并上调 GPX4 表达。此外，该化合物表现出比Fer-1更优异的微粒体稳定性。目前的结果表明，该化合物是开发治疗血管疾病的新型铁死亡抑制剂的有前途的先导化合物。

  DOI：

  10.1016/j.bmc.2024.117716
• 作为产物：
  描述：

  2-萘甲醇 在 dipotassium hydrogenphosphate 作用下， 以 乙酸乙酯 为溶剂， 反应 1.5h， 生成 tert-butyl 4-(naphthalen-2-ylmethyl)piperazine-1-carboxylate
  参考文献：
  名称：

  通过异脲中间体对醇进行机械化学亲核取代**

  摘要：

  更环保的胺合成：首次提出了在机械化学单罐反应条件下通过反应性异脲盐对醇进行的亲核取代。该方法打开了获得生物活性胺的途径，包括活性药物成分。

  DOI：

  10.1002/cssc.202102286

文献信息

• De Novo Design, Synthesis and Evaluation of Benzylpiperazine Derivatives as Highly Selective Binders of Mcl-1
  作者：Xiao Ding、Yan Li、Li Lv、Mi Zhou、Li Han、Zhengxi Zhang、Qian Ba、Jingquan Li、Hui Wang、Hong Liu、Renxiao Wang

  DOI：10.1002/cmdc.201300316

  日期：2013.12

  protein can hopefully reduce the adverse side effects in chemotherapy treatments of cancers overexpressing different Bcl‐2 family proteins. In this study, we designed four series of benzylpiperazine derivatives as plausible Bcl‐2 inhibitors based on the outcomes of a computational algorithm. A total of 81 compounds were synthesized, and their binding affinities to Bcl‐2, Bcl‐xL, and Mcl‐1 measured. Encouragingly

  在开发抗凋亡B细胞淋巴瘤2（Bcl-2）家族蛋白（例如Bcl-2，Bcl-x L和Mcl-1）的小分子抑制剂方面已作了相当大的努力，以开发新型的抗癌药物疗法。与整个家族的一般抑制剂不同，每种成员蛋白的选择性抑制剂有望减少过度表达不同Bcl-2家族蛋白的癌症在化疗中的不良副作用。在这项研究中，我们基于计算算法的结果，设计了四个系列的苄基哌嗪衍生物作为合理的Bcl-2抑制剂。总共合成了81种化合物，并测量了它们与Bcl-2，Bcl-x L和Mcl-1的结合亲和力。令人鼓舞的是，22种化合物的结合亲和力在微摩尔范围内（K i < 20μM）至少一种靶蛋白。此外，观察到一些化合物是高选择性的粘结剂以Mcl-1的，没有可检测的结合Bcl-2的或Bcl-X大号，其中最有效的一个具有ķ我的0.18值μ中号为Mcl-1的。四种选定化合物与Mcl-1和Bcl-x L的结合模式通过分子对接和分子动力学模拟得出
• Pyrazole compounds and methods of making and using same
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US10093630B2

  公开（公告）日：2018-10-09

  Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain, solid tumors and/or obesity.

  本文提供了吡唑化合物和包含所述化合物的药物组合物。所述化合物和组合物可用作 MAGL、ABHD6 和 FAAH 中一种或多种的调节剂。此外，所述化合物和组合物还可用于治疗疼痛、实体瘤和/或肥胖症等。
• Discovery libraries targeting the major enzyme classes: The serine hydrolases
  作者：Katerina Otrubova、Venkat Srinivasan、Dale L. Boger

  DOI：10.1016/j.bmcl.2014.06.063

  日期：2014.8

  Two libraries of modestly reactive ureas containing either electron-deficient acyl anilines or acyl pyrazoles were prepared and are reported as screening libraries for candidate serine hydrolase inhibitors. Within each library is a small but powerful subset of compounds that serve as a chemotype fragment screening library capable of subsequent structural diversification. Elaboration of the pyrazole-based ureas provided remarkably potent irreversible inhibitors of fatty acid amide hydrolase (FAAH, apparent Ki=100-200 pM) complementary to those previously disclosed enlisting electron-deficient aniline-based ureas.
• Characterization of Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases
  作者：Jonathan Z. Long、Xin Jin、Alexander Adibekian、Weiwei Li、Benjamin F. Cravatt

  DOI：10.1021/jm9016976

  日期：2010.2.25

  Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) are two enzymes froth the serine hydrolase superfamily that degrade the endocannabinoids 2-arachidonoylglycerol and anandamide, respectively. We have recently discovered that MAGL and FAAH arc both inhibited by carbamates bearing an N-piperidine/piperazine group. Piperidine/piperazine carbamates show excellent in vivo activity, raising brain endocannabinoid levels and producing CBI-dependent behavioral effects in mice, suggesting that they represent a promising class of inhibitors for studying the endogenous functions of MAGL and FAAH. Herein, we disclose a full account of the syntheses, structure-activity relationships, and inhibitory activities of piperidine/piperazine carbamates against members of the serine hydrolase family. These scaffolds can be tuned for MAGL-selective or dual MAGL-FAAH inhibition by the attachment of an appropriately substituted bisarylcarbinol or aryloxybenzyl moiety, respectively, on the piperidine/piperazine ring. Modifications to the piperidine/piperazine ring ablated inhibitory activity, suggesting a strict requirement for a six-membered ring to maintain potency.
• PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US20170190669A1

  公开（公告）日：2017-07-06

  Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain, solid tumors and/or obesity.